iCardio
iCardio.ai is a Los Angeles–based deep learning company focused on automating the interpretation of echocardiography—one of the most widely performed imaging examinations in medicine. The company’s ambition is to build the world’s most comprehensive artificial intelligence platform for echocardiographic interpretation. The technology platform is made possible by unique access to proprietary datasets comprising millions of in-patient and out-patient echocardiographic studies. Leveraging this unprecedented data resource, iCardio.ai is developing deep learning systems capable of automating the full echocardiographic workflow. Today, iCardio.ai collaborates with several of the world’s leading ultrasound and healthcare technology companies—including Butterfly Network and Abbott Laboratories—to deliver its technology to clinicians globally. In February 2024, iCardio.ai received Breakthrough Device Designation from the U.S. Food and Drug Administration for its aortic stenosis screening algorithm, which enables earlier detection and more efficient referral of patients along their cardiovascular care pathways, and the company achieved two landmark FDA clearances for its EchoMeasure and CardioVision products. iCardio.ai is currently incubating in partnership with Cedars-Sinai, a globally recognized and leading research institution in cardiovascular medicine.